Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and the Risk of Cirrhosis in Patients with Chronic Hepatitis B—A Retrospective Cohort Study

References

• Maclachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med. 2015;5(5):a021410. doi:10.1101/cshperspect.a021410
   PubMed Web of Science ®Google Scholar
• Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477–491. doi:10.1053/j.gastro.2018.08.065
   PubMed Web of Science ®Google Scholar
• Liu K, Choi J, Le A, Yip TC, Wong GL. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. Aliment Pharmacol Ther. 2019;50(9):1037–1048. doi:10.1111/apt.15499
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Eslam M, et al. Liver diseases in the Asia-Pacific region: a lancet gastroenterology & hepatology commission. Lancet Gastroenterol Hepatol. 2020;5(2):167–228.
   PubMed Web of Science ®Google Scholar
• Eslam M, Sanyal AJ, Mafld: GJ, Consensus-Driven Proposed A. Nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):e1991. doi:10.1053/j.gastro.2019.11.312
   Web of Science ®Google Scholar
• Eslam M, Newsome PN, Anstee QM, Targher G, George J. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar
• Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’. Liver Int. 2020;40(6):1254–1261. doi:10.1111/liv.14478
   PubMed Web of Science ®Google Scholar
• Ciardullo S, Perseghin G. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. Liver Int. 2021;41(6):1290–1293. doi:10.1111/liv.14828
   PubMed Web of Science ®Google Scholar
• Lin S, Huang J, Wang M, Kumar R, Zhu Y. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver International. 2020;40(9):2082–2089. doi:10.1111/liv.14548
   PubMed Web of Science ®Google Scholar
• Huang J, Xue W, Wang M, MAFLD CriteriaMay YW. Overlook a subtype of patient with steatohepatitis and significant fibrosis. Diabetes Metab Syndr Obes. 2021;14:3417–3425. doi:10.2147/DMSO.S316096
   Web of Science ®Google Scholar
• Liu Z, Suo C, Shi O, et al. The health impact of MAFLD, a Novel Disease Cluster of NAFLD, is amplified by the integrated effect of fatty liver disease-related genetic variants. Clin Gastroenterol Hepatol. 2022;20(4):e855–e875. doi:10.1016/j.cgh.2020.12.033
   Web of Science ®Google Scholar
• Li H, Guo M, An Z, et al. Prevalence and risk factors of metabolic associated fatty liver disease in Xinxiang, China. Int J Environ Res Public Health. 2020;17:6.
   Web of Science ®Google Scholar
• Chen X, Zhou J, Wu L, Zhu X, Deng H. MAFLD is associated with the risk of liver fibrosis and inflammatory activity in HBeAg-negative CHB patients. Diabetes Metab Syndr Obes. 2022;15:673–683. doi:10.2147/DMSO.S351492
   PubMed Web of Science ®Google Scholar
• Yun BL, Ha Y, Chon YE, Mi NK, Hwang SG. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B. Clin Mol Hepatol. 2018;25(1):52–64.
   Web of Science ®Google Scholar
• Mak L, Hui R, Fung J, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol. 2020;73(4):800–806. doi:10.1016/j.jhep.2020.05.040
   PubMed Web of Science ®Google Scholar
• Mak LY, Seto WK, Hui RW, et al. Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval. J Viral Hepat. 2019;26(7):818–827. doi:10.1111/jvh.13095
   PubMed Web of Science ®Google Scholar
• Mak LY, Hui RW, Fung J, et al. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. Hepatol Int. 2021;15(4):901–911. doi:10.1007/s12072-021-10218-2
   PubMed Web of Science ®Google Scholar
• Li J, Yang HI, Yeh ML, Le MH, Nguyen MH. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and HBsAg seroclearance in chronic hepatitis B. J Infect Dis. 2020;224(2):294–302. doi:10.1093/infdis/jiaa739
   Web of Science ®Google Scholar
• Chinese Society of Infectious Diseases, Chinese Medical Association. Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (2019 version). J Chin Hepatol. 2019;35(12):2648–2669.
   Google Scholar
• Fan JG, Wei L, Zhuang H. National workshop on fatty liver and alcoholic liver disease, Chinese Society of Hepatology, Chinese Medical Association; fatty liver expert committee, Chinese medical doctor association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018. J Prac Hepatol. 2018;26(3):195–203.
   Google Scholar
• Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis. J Chin Hepatol. 2019;35(11):846–865.
   Google Scholar
• Tan K, Consultation WE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–163.
   Web of Science ®Google Scholar
• Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656–664. doi:10.1093/aje/kwn164
   PubMed Web of Science ®Google Scholar
• Kim Y, Chang Y, Cho YK, Jiin A, Hocheol S, Seungho R. Obesity and weight gain are associated with progression of fibrosis in patients with non-alcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(3):e542. doi:10.1016/j.cgh.2018.07.006
   Web of Science ®Google Scholar
• Wong RJ, Tran T, Kaufman H, Niles J, Gish R. Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis. PLoS One. 2019;14(8):e0220612. doi:10.1371/journal.pone.0220612
   Web of Science ®Google Scholar
• Hsiang J, Wong G, Chan H, et al. Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B. Aliment Pharmacol Ther. 2014;40(6):716–726. doi:10.1111/apt.12874
   Web of Science ®Google Scholar
• Seto WK, Hui RW, Mak LY, et al. Association between hepatic steatosis, measured by controlled attenuation parameter, and fibrosis burden in chronic hepatitis B. Clin Gastroenterol Hepatol. 2018;16(4):e572. doi:10.1016/j.cgh.2017.09.044
   Web of Science ®Google Scholar
• Natarajan Y, Kramer J, Yu X. Risk of cirrhosis and hepatocellular cancer in patients with NAFLD and normal liver enzymes. Hepatology. 2020;72(4):1242–1252. doi:10.1002/hep.31157
   Web of Science ®Google Scholar
• Wong S, Chan W, Mohamed R. Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B. J Viral Hepat. 2020;27(12):1297–1305. doi:10.1111/jvh.13361
   PubMed Web of Science ®Google Scholar
• Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;40(12):3018–3030. doi:10.1111/liv.14675
   PubMed Web of Science ®Google Scholar
• Le AK, Yang HI, Yeh ML, Jin M, Nguyen MH. Development and validation of a risk score for liver cirrhosis prediction in untreated and treated chronic hepatitis B. J Infect Dis. 2020;223(1):139–146. doi:10.1093/infdis/jiaa330
   Web of Science ®Google Scholar
• Charatcharoenwitthaya P, Pongpaibul A, Kaosombatwattana U, et al. The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response. Liver Int. 2017;37(4):542–551. doi:10.1111/liv.13271
   PubMed Web of Science ®Google Scholar
• Mak L, Lee C, Cheung KS, Wong D, Seto W. Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long‐term nucleoside analogue. Liver Int. 2019;39(7):1217–1225. doi:10.1111/liv.14104
   Web of Science ®Google Scholar
• Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(9):2672–2682. doi:10.1002/hep.30251
   Web of Science ®Google Scholar
• Clarembeau F, Bale G, Lanthier N. Cirrhosis and insulin resistance: current knowledge, pathophysiological mechanisms, complications and potential treatments. Clin Sci. 2020;134(16):2117–2135. doi:10.1042/CS20200022
   Web of Science ®Google Scholar